Table 1.

General data for the study population.

CharacteristicN
Sex, female/male205/193
Age*, yrs66 (53, 72)
ANCA by ELISA (MPO/PR3)357/41
Diagnosis, MPA/GPA/RLV269/104/25
Serum creatinine*, µmol/l333.5 (127.8, 638.5)
Creatinine clearance rate*, ml/min16.08 (7.13, 42.74)
BVAS*20 (15–24)
Five Factor Score*1 (1, 2)
Fever, n (%)226/398 (56.8)
Fatigue, n (%)258/398 (64.8)
Weight loss, n (%)215/398 (54.0)
Muscle pain, n (%)110/398 (27.6)
Arthralgia, n (%)125/398 (31.4)
Rash, n (%)77/398 (19.4)
Pulmonary involvement, n (%)280/398 (70.4)
  Pulmonary hemorrhage, n (%)138/398 (34.67)
  Pulmonary nodules/cavities, n (%)71/398 (17.84)
  Pulmonary interstitial fibrosis, n (%)147/398 (36.93)
Renal involvement, n (%)371/398 (93.2)
Ophthalmic, n (%)84/398 (21.1)
Ear, nose, throat manifestations, n (%)177/398 (44.5)
Upper respiratory tract, n (%)90/398 (22.7)
Gastrointestinal**, n (%)58/398 (14.6)
Nervous system, n (%)82/398 (20.6)
  • * Data are 50th centile (25th, 75th centiles);

  • ** Gastrointestinal bleeding, perforation, infarction and/or pancreatitis26. BVAS: Birmingham Vasculitis Activity Score; GPA: granulomatosis with polyangiitis; MPA: microscopic polyangiitis; RLV: renal-limited vasculitis; ANCA: antineutrophil cytoplasmic antibody; MPO: myeloperoxidase; PR3: proteinase-3.